Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions

Enveric Biosciences Inc ENVB, a biotechnology company focused on neuropsychiatric treatment development, has secured five new U.S. patents for its EVM301 portfolio.

This latest additions bring Enveric's total to nine issued U.S. patents, enhancing the intellectual property surrounding its library of neuroplasticity-focused compounds aimed at mental health conditions.

“The addition of these patents not only bolsters Enveric's efforts in neuropsychiatric disorders but also provides exciting opportunities to explore the therapeutic potential of our compounds in a variety of other medical fields," Dr. Joseph Tucker, CEO of Enveric told Benzinga exclusively.

See Also: Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic

The newly patented compounds expand Enveric's range of tryptamine derivatives, developed through its proprietary Psybrary platform.

This platform includes over 1,000 tryptamine-based molecules, cataloging data on receptor engagement and biological activity.

Neuropsychiatric Milestone

Enveric's EVM301 portfolio focuses on various molecule types, including carboxylated, aminated, prenylated and halogenated derivatives, as well as combinations of multiple functional motifs.

“This milestone in our IP journey reflects Enveric's relentless drive to innovate in the neuropsychiatric field,” Tucker said. “By securing robust patent protection across our EVM301 portfolio, we're building a strong foundation for the long-term success and impact of our drug development efforts."

Lead Candidate EB-003 Moves Forward

Among its drug candidates, Enveric's lead compound, EB-003, targets treatment-resistant depression and anxiety. It is currently in preclinical stages with an Investigational New Drug (IND) filing expected in 2025.

EB-003 is designed to support neuroplasticity without inducing hallucinations, a property that could make it a safer option for patients. Initial receptor engagement studies suggest a favorable safety profile, which, according to Enveric, could help broaden the scope of accessible treatment options.

“EB-003, as our lead candidate from the EVM301 portfolio, exemplifies the therapeutic promise of our neuroplastogen approach,” Tucker explained. “Our data suggest it has the potential to treat major mental health conditions without the safety risks associated with hallucinations, moving us closer to a safer, more effective therapeutic solution."

Read Next:

• Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences’ Breakthrough Research

Cover image made with AI.